Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary

Anti–PD-1 in Combination With Trametinib Suppresses Tumor Growth and Improves Survival of Intrahepatic Cholangiocarcinoma in MiceSummary

Background & Aims: Intrahepatic cholangiocarcinoma (iCCA) accounts for a fraction of primary liver cancers but has a 5-year survival rate of only 10%. Immune checkpoint inhibitors are effective in treating many solid cancers, but immune checkpoint inhibitor monotherapy has no clear benefit i...

Full description

Bibliographic Details
Main Authors: Simon Wabitsch, Mayank Tandon, Benjamin Ruf, Qianfei Zhang, Justin D. McCallen, John C. McVey, Chi Ma, Benjamin L. Green, Laurence P. Diggs, Bernd Heinrich, Tim F. Greten
Format: Article
Language:English
Published: Elsevier 2021-01-01
Series:Cellular and Molecular Gastroenterology and Hepatology
Subjects:
Intrahepatic Cholangiocarcinoma
Anti–PD-1 Monoclonal Antibody
Trametinib
Online Access:http://www.sciencedirect.com/science/article/pii/S2352345X21001004

Internet

http://www.sciencedirect.com/science/article/pii/S2352345X21001004

Similar Items